| Previous Close | 1.4200 |
| Open | 0.8950 |
| Bid | 0.9280 x 1200 |
| Ask | 0.9400 x 2900 |
| Day's Range | 0.8899 - 0.9480 |
| 52 Week Range | 0.8899 - 15.0000 |
| Volume | 10,176,866 |
| Avg. Volume | 1,239,040 |
| Market Cap | 42.329M |
| Beta (3Y Monthly) | 0.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock and accompanying short-term warrants to purchase up to 15,000,000 shares of its common stock and long-term warrants to purchase up to 15,000,000 shares of its common stock (collectively, the “warrants”). Each share of common stock is being sold together with one short-term warrant to purchase one share of common stock and one long-term warrant to purchase one share of common stock, at a combined price to the public of $1.00 per share of common stock and accompanying warrants, for gross proceeds of $15 million, before deducting underwriting discounts and commissions and offering expenses payable by Achaogen.
Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Achaogen. In addition, Achaogen expects to grant the underwriter of the offering a 30-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.
Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it has responded to a Request for Information (RFI) regarding antibacterial products with the potential to treat resistant biothreat pathogens. The RFI was solicited by the Assistant Secretary for Preparedness and Response (ASPR) / the Biomedical Advanced Research and Development Authority (BARDA) under Project BioShield. The RFI specifically requested information on availabilities and capabilities for procuring, stockpiling and investing in the ongoing development of antibiotic products for commercial use for treatment of multiple biodefense indications, including pneumonic plague and tularemia, for which plazomicin has demonstrated preclinical efficacy.
Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today shared certain key preliminary unaudited results for the fourth quarter ended December 31, 2018, and provided an update on its commercial and corporate activities. “As our previously announced review of strategic alternatives continues, I am pleased with the steady progress of the ZEMDRI commercial launch and especially the commitment of the entire company to bringing this important medicine to the infectious disease community,” said Blake Wise, Achaogen’s Chief Executive Officer.
NEW YORK, NY / ACCESSWIRE / December 11, 2018 / Arcadia Biosciences and Achaogen were two winners in the biotech arena on Monday. Achaogen soared over 20% on positive clearance news for the Thermo Scientific QMS Plazomicin Immunoassay. There was no remarkable news from Arcadia Biosciences to explain the jump.
NEW YORK, Dec. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial.
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Achaogen, Inc. (NASDAQ: AKAO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern Time. To ...